- Home
- LPA vs MREO Comparison
LPA vs MREO Comparison
Compare LPA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- MREO
- Stock Information
- Founded
- LPA 2013
- MREO 2015
- Country
- LPA United States
- MREO United Kingdom
- Employees
- LPA N/A
- MREO N/A
- Industry
- LPA
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- LPA
- MREO Health Care
- Exchange
- LPA Nasdaq
- MREO Nasdaq
- Market Cap
- LPA 310.7M
- MREO 369.2M
- IPO Year
- LPA N/A
- MREO N/A
- Fundamental
- Price
- LPA $6.80
- MREO $2.30
- Analyst Decision
- LPA
- MREO Strong Buy
- Analyst Count
- LPA 0
- MREO 7
- Target Price
- LPA N/A
- MREO $7.71
- AVG Volume (30 Days)
- LPA 17.2K
- MREO 1.7M
- Earning Date
- LPA 05-14-2025
- MREO 05-14-2025
- Dividend Yield
- LPA N/A
- MREO N/A
- EPS Growth
- LPA N/A
- MREO N/A
- EPS
- LPA N/A
- MREO N/A
- Revenue
- LPA $43,862,372.00
- MREO N/A
- Revenue This Year
- LPA N/A
- MREO N/A
- Revenue Next Year
- LPA N/A
- MREO $61.92
- P/E Ratio
- LPA N/A
- MREO N/A
- Revenue Growth
- LPA 11.22
- MREO N/A
- 52 Week Low
- LPA $6.00
- MREO $1.58
- 52 Week High
- LPA $525.00
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- LPA N/A
- MREO 52.99
- Support Level
- LPA N/A
- MREO $1.58
- Resistance Level
- LPA N/A
- MREO $2.37
- Average True Range (ATR)
- LPA 0.00
- MREO 0.21
- MACD
- LPA 0.00
- MREO 0.04
- Stochastic Oscillator
- LPA 0.00
- MREO 91.19
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).